Summit Therapeutics (SUMM)

 

Latest News

Summit Enrolls Patients in the US into PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid

A statement giving an update on research (e.g. clinical trials)

Summit Therapeutics plc : Exercise of Options

Notification of an issue of equity shares e.g. offer for subscription/offer for sale/rights issue

Summit Therapeutics plc : Holding(s) in Company

Notification of major interests in shares

Summit Therapeutics plc : Exercise of Options

Notification of an issue of equity shares e.g. offer for subscription/offer for sale/rights issue

All News

DateHeadlineSource
16-11-16Summit Enrolls Patients in the US into PhaseOut DMD, a Phase 2 Clinical Trial of EzutromidRNS
24-10-16Summit Therapeutics plc : Exercise of OptionsRNS
19-10-16Summit Therapeutics plc : Holding(s) in CompanyRNS
14-10-16Summit Therapeutics plc : Exercise of OptionsRNS
11-10-16Summit Therapeutics plc : Exercise of OptionsRNS
07-10-16Summit Therapeutics plc : Exercise of OptionsRNS
06-10-16Summit Presents Preclinical DMD Data at 21st Congress of World Muscle SocietyRNS
04-10-16FTSE closes close to its record high StockMarketWire
04-10-16Why Summit Therapeutics just doubledInteractive Investor
04-10-16Summit Files Form 6-K on Licensing and Collaboration Agreement with Sarepta and Updated Cash GuidanceRNS
04-10-16Summit to Host Conference Call to Discuss Exclusive License and Collaboration Agreement with SareptaRNS
04-10-16Sarepta Therapeutics and Summit Enter into Exclusive License and Collaboration AgreementRNS
28-09-16Summit Therapeutics plc : Holding(s) in CompanyRNS
27-09-16Summit Received Rare Pediatric Disease Designation from US FDA for Ezutromid in Treatment of DMDRNS
26-09-16Summit Receives Fast Track Designation from US FDA for Ezutromid in the Treatment of DMDRNS
08-09-16Summit Therapeutics widens H1 lossStockMarketWire
08-09-16Summit Therapeutics plc : Half-yearly reportRNS
07-09-16Summit Therapeutics to Present at 18th Annual Rodman & Renshaw Global Investment ConferenceRNS
05-09-16Summit Therapeutics plc : Notice of ResultsRNS
09-08-16Summit Reports Positive Phase 1 Data and Outlines Route to Market Strategy for DMD Candidate EzutromidRNS
05-08-16Summit Therapeutics to Present at Canaccord Genuity Growth ConferenceRNS
18-07-16Summit Therapeutics plc : Result of AGMRNS
28-06-16Summit Therapeutics plc : Exercise of OptionsRNS
24-06-16Summit Therapeutics plc : Award of OptionsRNS
21-06-16Summit's Ridinilazole Preserves Microbiome During Treatment of C. Difficile InfectionRNS
17-06-16Summit Therapeutics plc : Notice of AGMRNS
17-06-16First Patient Enrolled in Summit's PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Boys with DMDRNS
16-06-16Summit Therapeutics to Present at JMP Securities Life Sciences ConferenceRNS
08-06-16Summit Therapeutics to Host Utrophin R&D Day 15 June 2016RNS
02-06-16Summit Therapeutics plc : 1st Quarter ResultsRNS
31-05-16Summit Therapeutics plc : Notice of ResultsRNS
23-05-16Summit to Present Phase 2 CoDIFy Trial Data at ASM Microbe 2016RNS
12-05-16Summit Therapeutics File US Annual Report on Form 20-FRNS
10-05-16Summit's FY net losses widenStockMarketWire
10-05-16Summit Therapeutics Reports Financial Results for Q4 and Fiscal Year Ended 31 January 2016RNS
06-05-16Summit Therapeutics plc : Notice of ResultsRNS
28-04-16Summit granted further US patent for ridinilazoleStockMarketWire
28-04-16Summit Announces Further US Patent Granted for CDI Antibiotic RidinilazoleRNS
26-04-16Summit's IND cleared by FDAStockMarketWire
26-04-16Summit's IND Cleared by FDA Allowing Expansion of PhaseOut DMD, a Phase 2 Clinical Trial of EzutromidRNS

RSS feeds

  • Editorial news feed for LSE:SUMM Editorial
  • Regulatory news feed for LSE:SUMM Regulatory